The approval of Novartis' CAR-T leukemia treatment is ushering in a new class of lifesaving products, but at a high cost. Here's how one oncologist is working to make cancer care more effective for patients, doctors and payers alike.
from Forbes Real Time //www.forbes.com/sites/arleneweintraub/2017/08/31/a-cancer-doc-weighs-in-on-car-t-precision-medicine-and-pricing-debates/
via IFTTT
No comments:
Post a Comment